SCHEMBL3798419

SCHEMBL3798419

Cc1cc(C)cc(/C=C(\C(=O)N2CCOCC2)c2ccc(Oc3ccc(CC4SC(=O)NC4=O)cc3)cc2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 5/20 0.58
MAOA P21397 1/20 0.43
CISD1 Q9NZ45 1/20 0.43
ALDH1A1 P00352 4/20 0.41
NPSR1 Q6W5P4 1/20 0.41
FFAR1 O14842 6/20 0.41
HRH3 Q9Y5N1 1/20 0.41
MPC2 O95563 1/20 0.40
CYP2C8 P10632 1/20 0.40
CYP2C9 P11712 1/20 0.40
MAPT P10636 3/20 0.39
HPGD P15428 2/20 0.39
TDP1 Q9NUW8 2/20 0.39
MEN1 O00255 1/20 0.39
TP53 P04637 1/20 0.39
CYP1A2 P05177 1/20 0.39
CYP3A4 P08684 1/20 0.39
ALOX15 P16050 1/20 0.39
TSHR P16473 1/20 0.39
KMT2A Q03164 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3798422 1.00 PPARG (0.58) PPARGMAOACISD1ALDH1A1NPSR1
SCHEMBL13347280 1.00 PPARG (0.58) PPARGMAOACISD1ALDH1A1NPSR1
SCHEMBL3801927 0.84 PPARG (0.68) PPARGMAOACISD1ALDH1A1NPSR1
SCHEMBL3801924 0.84 PPARG (0.68) PPARGMAOACISD1ALDH1A1NPSR1
SCHEMBL3792635 0.83 PPARG (0.83) PPARGMAOACISD1ALDH1A1NPSR1
SCHEMBL3792638 0.83 PPARG (0.83) PPARGMAOACISD1ALDH1A1NPSR1
SCHEMBL3585248 0.77 HRH3 (0.50) PPARGALDH1A1NPSR1FFAR1HRH3
SCHEMBL3797572 0.76 PPARG (0.64) PPARGMAOACISD1ALDH1A1NPSR1
SCHEMBL3797571 0.76 PPARG (0.64) PPARGMAOACISD1ALDH1A1NPSR1
SCHEMBL13347268 0.76 PPARG (0.64) PPARGMAOACISD1ALDH1A1NPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060235062-A1 Novel heterocyclic analogs of diphenylethylene compounds THERACOS, INC. (US) 2006-10-19 US claimed
US-20030181494-A1 Novel heterocyclic analogs of diphenylethylene compounds SEED, BRIAN 2003-09-25 US claimed
US-7718682-B2 Heterocyclic analogs of diphenylethylene compounds THERACOS, INC. (US) 2010-05-18 US disclosed
US-20080293949-A1 Novel heterocyclic analogs of diphenylethylene compounds THERACOS, INC. (US) 2008-11-27 US disclosed
US-7407978-B2 Heterocyclic analogs of diphenylethylene compounds THERACOS, INC. (US) 2008-08-05 US disclosed
US-20060235062-A1 Novel heterocyclic analogs of diphenylethylene compounds THERACOS, INC. (US) 2006-10-19 US disclosed
EP-1549625-A1 NOVEL HETEROCYCLIC ANALOGS OF DIPHENYLETHYLENE COMPOUNDS Theracos, Inc. (US) 2005-07-06 EP disclosed
WO-2004033438-A1 NOVEL HETEROCYCLIC ANALOGS OF DIPHENYLETHYLENE COMPOUNDS THERACOS, INC. (US) 2004-04-22 WO disclosed
US-20030181494-A1 Novel heterocyclic analogs of diphenylethylene compounds SEED, BRIAN 2003-09-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030181494-A1 Novel heterocyclic analogs of diphenylethylene compounds FFAR2, FFAR4, GPR119 PPARG 10/4885MAOA 3551/4885CISD1 1151/4885
US-20060235062-A1 Novel heterocyclic analogs of diphenylethylene compounds FFAR2, FFAR4, GPR119 PPARG 10/4885MAOA 3551/4885CISD1 1151/4885
US-20080293949-A1 Novel heterocyclic analogs of diphenylethylene compounds FFAR2, FFAR4, GPR119 PPARG 10/4885MAOA 3551/4885CISD1 1151/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.